Scott Grimes - Cardlytics CEO, Co-Founder and Director
| CDLX Stock | USD 11.52 0.85 6.87% |
CEO
Mr. Scott D. Grimes is Chief Executive Officer, CoFounder and Director of the Company. From 2005 to June 2008, Mr. Grimes was Senior Vice President and General Manager, Payments at Capital One Financial Corporation and, from 2003 to 2005, Mr. Grimes was Vice President, Strategy at Capital One Financial Corporationrationration. From 2001 to 2003, Mr. Grimes was a Principal at Canaan Partners, a VC firm. Earlier in his career, Mr. Grimes was a Senior Vice President at FreeMarkets Inc., an esourcing company, and a Principal at McKinsey Company, a management consulting firm. Mr. Grimes began his career at Schlumberger Limited as an electrical engineer. Since August 2014, Mr. Grimes has served as a director of Evergy, Inc., a regulated electric utility, where he also serves on the audit, finance and nuclear, operations, and environmental oversight committees
| Age | 55 |
| Professional Marks | MBA |
| Address | 675 Ponce de Leon Avenue NE, Atlanta, GA, United States, 30308 |
| Phone | 888 792 5802 |
| Web | https://www.cardlytics.com |
Cardlytics Management Efficiency
The company has return on total asset (ROA) of (0.0629) % which means that it has lost $0.0629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7777) %, meaning that it created substantial loss on money invested by shareholders. Cardlytics' management efficiency ratios could be used to measure how well Cardlytics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.6 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, Cardlytics' Net Tangible Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to rise to 0.62 in 2024, whereas Total Assets are likely to drop slightly above 440 M in 2024.Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.0629 |
Cardlytics Leadership Team
Elected by the shareholders, the Cardlytics' board of directors comprises two types of representatives: Cardlytics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardlytics. The board's role is to monitor Cardlytics' management team and ensure that shareholders' interests are well served. Cardlytics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardlytics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bryce Youngren, Independent Director | ||
| Carson Napps, Head People | ||
| Jose Singer, Chief Officer | ||
| John Hider, Vice President of Grocery and Partnerships | ||
| John Klinck, Independent Director | ||
| Scott Grimes, CEO, Co-Founder and Director | ||
| Aimee Lapic, Director | ||
| Alexis DeSieno, Chief Officer | ||
| James Hart, VP People | ||
| Amit Gupta, COO Bridg | ||
| John Balen, Independent Chairman of the Board | ||
| Kirk Esq, Sec | ||
| Peter Davies, Head Operations | ||
| Peter Chan, Chief Officer | ||
| Tony Weisman, Independent Director | ||
| David Adams, Independent Director | ||
| Evelyne Forester, Chief Officer | ||
| Jared Luskin, Senior Vice President for Growth Verticals | ||
| Lynne Laube, Co-Founder, COO, Director | ||
| David Evans, CFO & Head of Corporate Development | ||
| Kirk Somers, Chief Legal and Privacy Officer | ||
| Dani Cushion, Chief Marketing Officer | ||
| Fred Rolle, Chief Strategy Officer & President Bank Programs | ||
| Karim Temsamani, CEO Director | ||
| Nick Lynton, Chief Secretary | ||
| Craig Snodgrass, Chief Officer | ||
| Mark Johnson, Independent Director | ||
| Angie Amberg, Head Communications | ||
| Andrew Christiansen, Chief Officer | ||
| Dustin Renn, Senior Vice President of Corporate Development |
Cardlytics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardlytics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.0629 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 729.17 M | ||||
| Shares Outstanding | 48.17 M | ||||
| Shares Owned By Insiders | 3.30 % | ||||
| Shares Owned By Institutions | 63.84 % | ||||
| Number Of Shares Shorted | 5.95 M | ||||
| Price To Earning | (3.47) X |
Pair Trading with Cardlytics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardlytics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardlytics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardlytics Stock
| 0.66 | SE | Sea Financial Report 21st of May 2024 | PairCorr |
Moving against Cardlytics Stock
| 0.81 | EVC | Entravision Communications Earnings Call This Week | PairCorr |
| 0.77 | WMG | Warner Music Group Financial Report 14th of May 2024 | PairCorr |
| 0.74 | IAS | Integral Ad Science Sell-off Trend | PairCorr |
| 0.67 | WBD | Warner Bros Discovery Aggressive Push | PairCorr |
| 0.62 | BATRA | Atlanta Braves Holdings | PairCorr |
The ability to find closely correlated positions to Cardlytics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardlytics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardlytics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardlytics to buy it.
The correlation of Cardlytics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardlytics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardlytics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardlytics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardlytics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Cardlytics Stock please use our How to Invest in Cardlytics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Cardlytics Stock analysis
When running Cardlytics' price analysis, check to measure Cardlytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardlytics is operating at the current time. Most of Cardlytics' value examination focuses on studying past and present price action to predict the probability of Cardlytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardlytics' price. Additionally, you may evaluate how the addition of Cardlytics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Cardlytics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardlytics. If investors know Cardlytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardlytics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.57) | Earnings Share (3.69) | Revenue Per Share 8.474 | Quarterly Revenue Growth 0.081 | Return On Assets (0.06) |
The market value of Cardlytics is measured differently than its book value, which is the value of Cardlytics that is recorded on the company's balance sheet. Investors also form their own opinion of Cardlytics' value that differs from its market value or its book value, called intrinsic value, which is Cardlytics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardlytics' market value can be influenced by many factors that don't directly affect Cardlytics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardlytics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardlytics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardlytics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.